12/07/2022 Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
- Cetuximab 100 mg/20 mL solution for infusion; and
- Panitumumab 100 mg/5 mL concentrate for solution for infusion
as monotherapy or in combination with chemotherapy for treating RAS wild-type metastatic colorectal cancer.
Subsidy status
RPanitumumab 100 mg/5 mL concentrate for solution for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.
RCetuximab 100 mg/20 mL solution for infusion is recommended for inclusion on the SDL for the abovementioned indication with effect from 1 September 2022.
Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.